Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CTI BIOPHARMA CORP (CTI)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | | | | |
| Cost of goods sold | 5.5% | 6.3% | 7.4% | 12.1% | | | | |
| Gross profit | 94.5% | 93.7% | 92.6% | 87.9% | | | | |
| Selling, general and administrative | | 117.9% | 175.1% | 786.3% | | | | |
| Research and development | 56.5% | 45.1% | 70.6% | 350.7% | | | | |
| General and administrative | 112.4% | | | | | | | |
| Depreciation | 2.5% | 2.9% | 4.6% | 13.8% | | | | |
| EBIT | -64.5% | -67.0% | -153.2% | -1529.4% | | | | |
| Pre-tax income | -82.8% | -86.1% | -183.7% | -1619.8% | | | | |
| Income taxes | 0.0% | 0.0% | 0.0% | 0.0% | | | | |
| Net income | -82.8% | -86.1% | -183.7% | -1619.8% | | | | |
|